Clinical trials: S. Aureus Bloodstream Infection
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Staphylococcus Aureus Bloodstream Infection
A Phase I Study of XJ101 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria.
- Trial name
- NCT06014736
- Testing
- XJ101 for Injection
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Starmab biologics（Shanghai）Co,.ltd
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Rheumatoid Arthritis, Staphylococcus Aureus Bacteremia
Bloodstream Infections in Patients With Rheumatoid Arthritis
Study of incidence and risk factors of staphylococcus aureus bacteremia in patients with rheumatoid arthritis compared with the general population in a nationwide cohort of all adult members of the population from 1996 until 2017…
- Trial name
- NCT03908086
- Testing
- Risk factors in RA cohort, Risk factors in general population
- Volunteers
- 6,000,000 people
- Sponsor
- Sabine Dieperink
Staphylococcus Aureus
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in…
- Trial name
- NCT03140423
- Testing
- Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
- Where
- 137 sites in United States
- Volunteers
- 353,323 people
- Sponsor
- Harvard Pilgrim Health Care
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus
Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection
S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci of Infection (SA-DFI), which…
- Trial name
- TEPSTAR (NCT03419221)
- Testing
- PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions, Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
- Where
- France
- Volunteers
- 291 people
- Sponsor
- University Hospital, Montpellier
Staphylococcus Aureus, Bacteremia
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.
- Conditions
- Staphylococcus Aureus, Bacteremia, Endocarditis, Sepsis
- Trial name
- FINLEVO (NCT00548002)
- Testing
- trovafloxacin and levofloxacin
- Where
- Finland
- Volunteers
- 430 people
- Sponsor
- University of Helsinki
Pneumonia, Bloodstream Infection
Clinical Outcomes in Patients With Infection by Resistant Microorganism
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and…
- Conditions
- Pneumonia, Bloodstream Infection, Urinary Tract Infections, Skin Infection
- Trial name
- NCT05880069
- Testing
- Pathogen resistant phenotype
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Universitario Virgen Macarena
Staphylococcus Aureus Infection
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade [1].
- Trial name
- SABATO (NCT01792804)
- Testing
- Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid
- Where
- 40 sites in France, Germany and 3 more
- Volunteers
- 215 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Staphylococcus Aureus Bacteremia
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral…
- Trial name
- EVOS (NCT06336824)
- Testing
- Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
- Where
- 12 sites in Malaysia
- Volunteers
- 290 people
- Sponsor
- Clinical Research Centre, Malaysia
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Diabetic Foot, Foot Ulcer
Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds
The primary objective of this study is to detect differences in anti-S. aureus antibody assays (IgM, IgA, IgG and its subclasses) between (1) a group of patients with bacteremia due to a chronic wound (cases) and (2) a group of…
- Conditions
- Diabetic Foot, Foot Ulcer, Leg Ulcer, Bacteremia
- Trial name
- ORISA (NCT01551667)
- Testing
- Antibody assays for S. aureus, Basic blood work
- Where
- 6 sites in France
- Volunteers
- 69 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre